首页/数据集/Clinical and Pathologic Response of the Primary Tumor in Women Receiving Neoadjuvant Docetaxel-Capecitabine (+/- Trastuzumab) Chemotherapy

Clinical and Pathologic Response of the Primary Tumor in Women Receiving Neoadjuvant Docetaxel-Capecitabine (+/- Trastuzumab) Chemotherapy

ChEBI2011-03-18 更新2026-07-21 收录

乳腺癌新辅助化疗

临床病理反应评估

数据链接：

https://www.ebi.ac.uk/biostudies/ArrayExpress/studies/E-GEOD-22358 数据链接链接失效反馈

官方服务：

资源简介：

Clinical and Pathologic Response of the Primary Tumor in Women Receiving Neoadjuvant Docetaxel-Capecitabine (+/- Trastuzumab) Chemotherapy

应用场景：

创建时间：

2011-03-18

乳腺癌新辅助化疗

治疗反应预测

Table S1. Gene lists of pairwise analysis of pre- and on-treatment sequential patient-matched samples from NEO and I-SPY datasets using Significance analysis of microarrays with FDR = 10%. Table S2. G

Figshare2019-06-14 更新50

MOESM1 of CAIX is a predictor of pathological complete response and is associated with higher survival in locally advanced breast cancer submitted to neoadjuvant chemotherapy

乳腺癌新辅助化疗

代谢蛋白表达

Additional file 1: Table S1. Association between metabolism-related proteins expression and clinicopathologic characteristics. Table showing the association between metabolism-related proteins express

NIAID Data Ecosystem30

Expression data from breast cancer FNA biopsies from patients ( (USO samples)

乳腺癌新辅助化疗

肿瘤基因表达

Tumor samples were obtained from patients with stage II-III breast cancer before starting neoadjuvant chemotherapy with four cycles of 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by four

NIAID Data Ecosystem30

Table S9 from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy

乳腺癌新辅助化疗

肿瘤免疫微环境

Table S9

NIAID Data Ecosystem30

Table_2_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study.docx

乳腺癌新辅助化疗

心脏毒性临床评估

BackgroundThe CAPRICE trial was designed to specifically evaluate neoadjuvant pegylated liposomal doxorubicin (PLD) in elderly patients or in those with other cardiovascular risk factors in whom conve

NIAID Data Ecosystem30

Clinical and Pathologic Response of the Primary Tumor in Women Receiving Neoadjuvant Docetaxel-Capecitabine (+/- Trastuzumab) Chemotherapy

资源简介：

相关数据集